Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Acquired by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. increased its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 9.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 55,770 shares of the biotechnology company’s stock after acquiring an additional 4,900 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Ironwood Pharmaceuticals were worth $364,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IRWD. Charles Schwab Investment Management Inc. lifted its position in shares of Ironwood Pharmaceuticals by 4.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,288,653 shares of the biotechnology company’s stock worth $14,742,000 after purchasing an additional 57,859 shares in the last quarter. Jump Financial LLC purchased a new stake in Ironwood Pharmaceuticals in the fourth quarter valued at approximately $389,000. Massachusetts Financial Services Co. MA purchased a new position in shares of Ironwood Pharmaceuticals during the fourth quarter worth approximately $1,129,000. Quadrant Capital Group LLC raised its position in Ironwood Pharmaceuticals by 68.8% in the 4th quarter. Quadrant Capital Group LLC now owns 8,578 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 3,497 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at about $9,321,000.

Ironwood Pharmaceuticals Stock Performance

Ironwood Pharmaceuticals stock opened at $4.47 on Tuesday. The firm has a market capitalization of $714.04 million, a price-to-earnings ratio of -0.66 and a beta of 0.49. The company has a 50 day moving average price of $5.50 and a 200 day moving average price of $6.73. Ironwood Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $15.70.

Analysts Set New Price Targets

A number of research firms recently weighed in on IRWD. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 16th. Wells Fargo & Company lowered their price target on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, August 9th. Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. Leerink Partners initiated coverage on shares of Ironwood Pharmaceuticals in a research report on Monday, September 9th. They issued a “market perform” rating and a $5.00 target price on the stock. Finally, Craig Hallum lowered their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Ironwood Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $13.57.

Insider Activity

In other news, insider Minardo John sold 9,910 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $4.27, for a total transaction of $42,315.70. Following the completion of the transaction, the insider now owns 284,661 shares of the company’s stock, valued at $1,215,502.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 12.90% of the stock is owned by insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.